1
|
Mehkri Y, Pierre K, Woodford SJ, Davidson CG, Urhie O, Sriram S, Hernandez J, Hanna C, Lucke-Wold B. Surgical Management of Brain Tumors with Focused Ultrasound. Curr Oncol 2023; 30:4990-5002. [PMID: 37232835 DOI: 10.3390/curroncol30050377] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 04/26/2023] [Accepted: 05/02/2023] [Indexed: 05/27/2023] Open
Abstract
Focused ultrasound is a novel technique for the treatment of aggressive brain tumors that uses both mechanical and thermal mechanisms. This non-invasive technique can allow for both the thermal ablation of inoperable tumors and the delivery of chemotherapy and immunotherapy while minimizing the risk of infection and shortening the time to recovery. With recent advances, focused ultrasound has been increasingly effective for larger tumors without the need for a craniotomy and can be used with minimal surrounding soft tissue damage. Treatment efficacy is dependent on multiple variables, including blood-brain barrier permeability, patient anatomical features, and tumor-specific features. Currently, many clinical trials are currently underway for the treatment of non-neoplastic cranial pathologies and other non-cranial malignancies. In this article, we review the current state of surgical management of brain tumors using focused ultrasound.
Collapse
Affiliation(s)
- Yusuf Mehkri
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Kevin Pierre
- Department of Radiology, College of Medicine, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32608, USA
| | - Samuel Joel Woodford
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Caroline Grace Davidson
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Ogaga Urhie
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Sai Sriram
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Jairo Hernandez
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Chadwin Hanna
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| | - Brandon Lucke-Wold
- Department of Neurosurgery, College of Medicine, University of Florida, 1505 SW Archer Rd, Gainesville, FL 32608, USA
| |
Collapse
|
2
|
Barzegar-Fallah A, Gandhi K, Rizwan SB, Slatter TL, Reynolds JNJ. Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier. Pharmaceutics 2022; 14:pharmaceutics14102231. [PMID: 36297666 PMCID: PMC9607160 DOI: 10.3390/pharmaceutics14102231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 10/11/2022] [Accepted: 10/17/2022] [Indexed: 11/16/2022] Open
Abstract
Despite significant advances in developing drugs to treat brain tumours, achieving therapeutic concentrations of the drug at the tumour site remains a major challenge due to the presence of the blood–brain barrier (BBB). Several strategies have evolved to enhance brain delivery of chemotherapeutic agents to treat tumours; however, most approaches have several limitations which hinder their clinical utility. Promising studies indicate that ultrasound can penetrate the skull to target specific brain regions and transiently open the BBB, safely and reversibly, with a high degree of spatial and temporal specificity. In this review, we initially describe the basics of therapeutic ultrasound, then detail ultrasound-based drug delivery strategies to the brain and the mechanisms by which ultrasound can improve brain tumour therapy. We review pre-clinical and clinical findings from ultrasound-mediated BBB opening and drug delivery studies and outline current therapeutic ultrasound devices and technologies designed for this purpose.
Collapse
Affiliation(s)
- Anita Barzegar-Fallah
- Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand
- Brain Health Research Centre, University of Otago, Dunedin 9016, New Zealand
| | - Kushan Gandhi
- Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand
- Brain Health Research Centre, University of Otago, Dunedin 9016, New Zealand
| | - Shakila B. Rizwan
- Brain Health Research Centre, University of Otago, Dunedin 9016, New Zealand
- School of Pharmacy, University of Otago, Dunedin 9016, New Zealand
| | - Tania L. Slatter
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand
| | - John N. J. Reynolds
- Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand
- Brain Health Research Centre, University of Otago, Dunedin 9016, New Zealand
- Correspondence: ; Tel.: +64-3-479-5781; Fax: +64-3-479-7254
| |
Collapse
|
3
|
Update in the clinical application of focused ultrasound. Curr Opin Neurol 2022; 35:525-535. [PMID: 35788096 DOI: 10.1097/wco.0000000000001073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW To review the most recent evidence about the clinical applicability of transcranial MRI-guided focused ultrasound (MRgFUS), including clinical evidence and indications, recent technical developments for its use and future prospects. RECENT FINDINGS Unilateral MRgFUS thalamotomy for both essential and parkinsonian tremors is an approved and well established therapy. Recent studies have focused on its long-term safety and efficacy as well as technical advances for refining the approach. Moreover, ultrasound has expanded its application in Parkinson's disease, with clinical trials successfully targeting other brain regions like the subthalamic nucleus, the globus pallidus and the pallidothalamic tract, providing benefits for features that thalamotomy neglects. New indications, such as focal dystonia or neuropsychiatric conditions (namely obsessive-compulsive disorder and depression) have also been explored, with encouraging preliminary results. Finally, the application of ultrasound in low-intensity modality allows other approaches like focal blood-brain barrier opening and neuromodulation, which promise to be highly relevant in translational research. SUMMARY MRgFUS is a growing emergent technique. Its application in clinical routine is becoming widely accepted as a therapeutic option. Novel approaches and new potential applications are anticipated.
Collapse
|
4
|
Binder DK, Shah BB, Elias WJ. Focused ultrasound and other lesioning in the treatment of tremor. J Neurol Sci 2022; 435:120193. [DOI: 10.1016/j.jns.2022.120193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 01/24/2022] [Accepted: 02/17/2022] [Indexed: 11/24/2022]
|
5
|
Kremer NI, Pauwels RWJ, Pozzi NG, Lange F, Roothans J, Volkmann J, Reich MM. Deep Brain Stimulation for Tremor: Update on Long-Term Outcomes, Target Considerations and Future Directions. J Clin Med 2021; 10:3468. [PMID: 34441763 PMCID: PMC8397098 DOI: 10.3390/jcm10163468] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 07/29/2021] [Accepted: 08/03/2021] [Indexed: 01/11/2023] Open
Abstract
Deep brain stimulation (DBS) of the thalamic ventral intermediate nucleus is one of the main advanced neurosurgical treatments for drug-resistant tremor. However, not every patient may be eligible for this procedure. Nowadays, various other functional neurosurgical procedures are available. In particular cases, radiofrequency thalamotomy, focused ultrasound and radiosurgery are proven alternatives to DBS. Besides, other DBS targets, such as the posterior subthalamic area (PSA) or the dentato-rubro-thalamic tract (DRT), may be appraised as well. In this review, the clinical characteristics and pathophysiology of tremor syndromes, as well as long-term outcomes of DBS in different targets, will be summarized. The effectiveness and safety of lesioning procedures will be discussed, and an evidence-based clinical treatment approach for patients with drug-resistant tremor will be presented. Lastly, the future directions in the treatment of severe tremor syndromes will be elaborated.
Collapse
Affiliation(s)
- Naomi I. Kremer
- Department of Neurosurgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; (N.I.K.); (R.W.J.P.)
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| | - Rik W. J. Pauwels
- Department of Neurosurgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; (N.I.K.); (R.W.J.P.)
| | - Nicolò G. Pozzi
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| | - Florian Lange
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| | - Jonas Roothans
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| | - Jens Volkmann
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| | - Martin M. Reich
- Department of Neurology, University Hospital and Julius-Maximilian-University, 97080 Wuerzburg, Germany; (N.G.P.); (F.L.); (J.R.); (J.V.)
| |
Collapse
|
6
|
Permezel F. Brain MRI-guided focused ultrasound conceptualised as a tool for brain network intervention. J Clin Neurosci 2021; 90:370-379. [PMID: 34275578 DOI: 10.1016/j.jocn.2021.05.062] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 05/02/2021] [Accepted: 05/27/2021] [Indexed: 11/25/2022]
Abstract
Magnetic resonance imaging guided high intensity focused ultrasound (HIFU) has emerged as a tool offering incisionless intervention on brain tissue. The low risk and rapid recovery from this procedure, in addition to the ability to assess for clinical benefit and adverse events intraprocedurally, makes it an ideal tool for intervention upon brain networks both for clinical and research applications. This review article proposes that conceptualising brain focused ultrasound as a tool for brain network intervention and adoption of methodology to complement this approach may result in better clinical outcomes, fewer adverse events and may unveil or allow treatment opportunities not otherwise possible. A brief introduction to network neuroscience is discussed before a description of pathological brain networks is provided for a number of conditions for which MRI-guided brain HIFU intervention has been implemented. Essential Tremor is discussed as the most advanced example of MRI-guided brain HIFU intervention adoption along with the issues that present with this treatment modality compared to alternatives. The brain network intervention paradigm is proposed to overcome these issues and a number of examples of implementation of this are discussed. The ability of low intensity MRI guided focussed ultrasound to neuromoduate brain tissue without lesioning is introduced. This tool is discussed with regards to its potential clinical application as well as its potential to further our understanding of network neuroscience via its ability to interrogate brain networks without damaging tissue. Finally, a number of current clinical trials utilising brain focused ultrasound are discussed, along with the additional applications available from the utilisation of low intensity focused ultrasound.
Collapse
Affiliation(s)
- Fiona Permezel
- Austin Hospital, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia; The Florey Institute of Neuroscience and Mental Health, Austin Hospital, Victoria, Australia.
| |
Collapse
|
7
|
Meng Y, Hynynen K, Lipsman N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol 2020; 17:7-22. [PMID: 33106619 DOI: 10.1038/s41582-020-00418-z] [Citation(s) in RCA: 180] [Impact Index Per Article: 45.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/16/2020] [Indexed: 02/07/2023]
Abstract
Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the clinic represents the culmination of decades of research. Lying at the convergence of physics, engineering, imaging, biology and neuroscience, FUS offers the ability to non-invasively and precisely intervene in key circuits that drive common and challenging brain conditions. The actions of FUS in the brain take many forms, ranging from transient blood-brain barrier opening and neuromodulation to permanent thermoablation. Over the past 5 years, we have seen a dramatic expansion of indications for and experience with FUS in humans, with a resultant exponential increase in academic and public interest in the technology. Applications now span the clinical spectrum in neurological and psychiatric diseases, with insights still emerging from preclinical models and human trials. In this Review, we provide a comprehensive overview of therapeutic ultrasound and its current and emerging indications in the brain. We examine the potential impact of FUS on the landscape of brain therapies as well as the challenges facing further advancement and broader adoption of this promising minimally invasive therapeutic alternative.
Collapse
Affiliation(s)
- Ying Meng
- Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Sunnybrook Research Institute, Hurvitz Brain Sciences Program, Harquail Centre for Neuromodulation, Toronto, ON, Canada.,Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
| | - Kullervo Hynynen
- Sunnybrook Research Institute, Toronto, ON, Canada.,Department of Medical Biophysics and Institute of Biomaterials & Biomedical Engineering (IBBME), University of Toronto, Toronto, ON, Canada
| | - Nir Lipsman
- Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. .,Sunnybrook Research Institute, Hurvitz Brain Sciences Program, Harquail Centre for Neuromodulation, Toronto, ON, Canada. .,Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
8
|
Todd N, McDannold N, Borsook D. Targeted manipulation of pain neural networks: The potential of focused ultrasound for treatment of chronic pain. Neurosci Biobehav Rev 2020; 115:238-250. [PMID: 32534900 PMCID: PMC7483565 DOI: 10.1016/j.neubiorev.2020.06.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 04/24/2020] [Accepted: 06/04/2020] [Indexed: 12/29/2022]
Abstract
Focused ultrasound (FUS) is a promising technology for facilitating treatment of brain diseases including chronic pain. Focused ultrasound is a unique modality for delivering therapeutic levels of energy into the body, including the central nervous system (CNS). It is non-invasive and can target spatially localized effects through the intact skull to cortical or subcortical regions of the brain. FUS can achieve three different mechanisms of action in the brain that are relevant for chronic pain treatment: (1) localized thermal ablation of neural tissue; (2) localized and transient disruption of the blood-brain barrier for targeted drug delivery to CNS structures; and (3) inhibition or stimulation of neuronal activity in targeted regions. This review provides an in-depth look at the technology of FUS with emphasis placed on applications to CNS-based treatments of chronic pain. While still in the early stages of clinical translation and with some technical challenges remaining, we suggest that FUS has great potential as a novel approach for manipulating CNS networks involved in pain treatment.
Collapse
Affiliation(s)
- Nick Todd
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; Center for Pain and the Brain, 1 Autumn Street, Boston Children's Hospital, Boston, MA, 02115, United States.
| | - Nathan McDannold
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
| | - David Borsook
- Center for Pain and the Brain, 1 Autumn Street, Boston Children's Hospital, Boston, MA, 02115, United States; Department of Anesthesia, Perioperative, and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, United States
| |
Collapse
|
9
|
Gallay MN, Moser D, Rossi F, Magara AE, Strasser M, Bühler R, Kowalski M, Pourtehrani P, Dragalina C, Federau C, Jeanmonod D. MRgFUS Pallidothalamic Tractotomy for Chronic Therapy-Resistant Parkinson's Disease in 51 Consecutive Patients: Single Center Experience. Front Surg 2020; 6:76. [PMID: 31993437 PMCID: PMC6971056 DOI: 10.3389/fsurg.2019.00076] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Accepted: 12/19/2019] [Indexed: 11/13/2022] Open
Abstract
Background: There is a long history, beginning in the 1940s, of ablative neurosurgery on the pallidal efferent fibers to treat patients suffering from Parkinson's disease (PD). Since the early 1990s, we undertook a re-actualization of the approach to the subthalamic region, and proposed, on a histological basis, to target specifically the pallidothalamic tract at the level of Forel's field H1. This intervention, the pallidothalamic tractotomy (PTT), has been performed since 2011 using the MR-guided focused ultrasound (MRgFUS) technique. A reappraisal of the histology of the pallidothalamic tract was combined recently with an optimization of our lesioning strategy using thermal dose control. Objective: This study was aimed at demonstrating the efficacy and risk profile of MRgFUS PTT against chronic therapy-resistant PD. Methods: This consecutive case series reflects our current treatment routine and was collected between 2017 and 2018. Fifty-two interventions in 47 patients were included. Fifteen patients received bilateral PTT. The median follow-up was 12 months. Results: The Unified Parkinson's Disease Rating Scale (UPDRS) off-medication postoperative score was compared to the baseline on-medication score and revealed percentage reductions of the mean of 84% for tremor, 70% for rigidity, and 73% for distal hypobradykinesia, all values given for the treated side. Axial items (for voice, trunk and gait) were not significantly improved. PTT achieved 100% suppression of on-medication dyskinesias as well as reduction in pain (p < 0.001), dystonia (p < 0.001) and REM sleep disorders (p < 0.01). Reduction of the mean L-Dopa intake was 55%. Patients reported an 88% mean tremor relief and 82% mean global symptom relief on the operated side and 69% mean global symptom improvement for the whole body. There was no significant change of cognitive functions. The small group of bilateral PTTs at 1 year follow-up shows similar results as compared to unilateral PTTs but does not allow to draw firm conclusions at this point. Conclusion: MRgFUS PTT was shown to be a safe and effective intervention for PD patients, addressing all symptoms, with varying effectiveness. We discuss the need to integrate the preoperative state of the thalamocortical network as well as the psycho-emotional dimension.
Collapse
Affiliation(s)
- Marc N Gallay
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| | - David Moser
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| | - Franziska Rossi
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| | | | - Maja Strasser
- Neurologische Praxis Solothurn, Solothurn, Switzerland
| | - Robert Bühler
- Neurological Division, Bürgerspital Solothurn, Solothurn, Switzerland
| | | | | | | | - Christian Federau
- Department of Radiology, University Hospital Basel, Basel, Switzerland.,Institute for Biomedical Engineering, ETH Zürich, University Zürich, Zurich, Switzerland
| | - Daniel Jeanmonod
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| |
Collapse
|
10
|
Pandit R, Chen L, Götz J. The blood-brain barrier: Physiology and strategies for drug delivery. Adv Drug Deliv Rev 2019; 165-166:1-14. [PMID: 31790711 DOI: 10.1016/j.addr.2019.11.009] [Citation(s) in RCA: 250] [Impact Index Per Article: 50.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 11/19/2019] [Accepted: 11/24/2019] [Indexed: 12/14/2022]
Abstract
The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper, reflecting the unique requirements of the brain. In this review, following a brief historical overview of how the concepts of the BBB and the neurovascular unit (NVU) developed, we describe its physiology and architecture, which pose a particular challenge to therapeutic intervention. We then discuss how the restrictive nature of this barrier can be overcome for the delivery of therapeutic agents. Alterations to drug formulation offer one option, in part by utilizing distinct transport modes; another is invasive or non-invasive strategies to bypass the BBB. An emerging non-invasive technology for targeted drug delivery is focused ultrasound that allows for the safe and reversible disruption of the BBB. We discuss the underlying mechanisms and provide an outlook, emphasizing the need for more research into the NVU and investment in innovative technologies to overcome the BBB for drug delivery.
Collapse
Affiliation(s)
- Rucha Pandit
- Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Liyu Chen
- Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia
| | - Jürgen Götz
- Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
| |
Collapse
|
11
|
Wang TR, Bond AE, Dallapiazza RF, Blanke A, Tilden D, Huerta TE, Moosa S, Prada FU, Elias WJ. Transcranial magnetic resonance imaging-guided focused ultrasound thalamotomy for tremor: technical note. Neurosurg Focus 2019; 44:E3. [PMID: 29385914 DOI: 10.3171/2017.10.focus17609] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Although the use of focused ultrasound (FUS) in neurosurgery dates to the 1950s, its clinical utility was limited by the need for a craniotomy to create an acoustic window. Recent technological advances have enabled efficient transcranial delivery of US. Moreover, US is now coupled with MRI to ensure precise energy delivery and monitoring. Thus, MRI-guided transcranial FUS lesioning is now being investigated for myriad neurological and psychiatric disorders. Among the first transcranial FUS treatments is thalamotomy for the treatment of various tremors. The authors provide a technical overview of FUS thalamotomy for tremor as well as important lessons learned during their experience with this emerging technology.
Collapse
Affiliation(s)
| | | | - Robert F Dallapiazza
- Division of Neurosurgery, Toronto Western Hospital University Health Network, Toronto, Ontario, Canada
| | | | | | - Thomas E Huerta
- Department of Radiology, Neuroradiology Division, University of Virginia Health System, Charlottesville, Virginia
| | | | - Francesco U Prada
- Department of Neurological Surgery, and.,Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
| | | |
Collapse
|
12
|
Harary M, Segar DJ, Huang KT, Tafel IJ, Valdes PA, Cosgrove GR. Focused ultrasound in neurosurgery: a historical perspective. Neurosurg Focus 2019; 44:E2. [PMID: 29385919 DOI: 10.3171/2017.11.focus17586] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Focused ultrasound (FUS) has been under investigation for neurosurgical applications since the 1940s. Early experiments demonstrated ultrasound as an effective tool for the creation of intracranial lesions; however, they were limited by the need for craniotomy to avoid trajectory damage and wave distortion by the skull, and they also lacked effective techniques for monitoring. Since then, the development and hemispheric distribution of phased arrays has resolved the issue of the skull and allowed for a completely transcranial procedure. Similarly, advances in MR technology have allowed for the real-time guidance of FUS procedures using MR thermometry. MR-guided FUS (MRgFUS) has primarily been investigated for its thermal lesioning capabilities and was recently approved for use in essential tremor. In this capacity, the use of MRgFUS is being investigated for other ablative indications in functional neurosurgery and neurooncology. Other applications of MRgFUS that are under active investigation include opening of the blood-brain barrier to facilitate delivery of therapeutic agents, neuromodulation, and thrombolysis. These recent advances suggest a promising future for MRgFUS as a viable and noninvasive neurosurgical tool, with strong potential for yet-unrealized applications.
Collapse
Affiliation(s)
- Maya Harary
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - David J Segar
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Kevin T Huang
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Ian J Tafel
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - Pablo A Valdes
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| | - G Rees Cosgrove
- Harvard Medical School and Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts
| |
Collapse
|
13
|
Gallay MN, Moser D, Federau C, Jeanmonod D. Radiological and Thermal Dose Correlations in Pallidothalamic Tractotomy With MRgFUS. Front Surg 2019; 6:28. [PMID: 31157233 PMCID: PMC6533852 DOI: 10.3389/fsurg.2019.00028] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 05/02/2019] [Indexed: 12/05/2022] Open
Abstract
Background: MR-guided focused ultrasound (MRgFUS) offers the possibility of safe and accurate lesioning inside the brain. Until now, most MRgFUS thermal applications have been based on temperature or energy protocols. Experimental studies support however an approach centered on thermal dose control. Objective: To show the technical feasibility and lesion size predictability of a thermal dose approach during MRgFUS pallidothalamic tractotomy (PTT) against chronic therapy-resistant Parkinson's disease (PD). Methods: MR and thermal dose data were analyzed in 31 MRgFUS interventions between January and December 2017 in patients suffering from chronic therapy-resistant Parkinson's disease (PD) using a standardized PTT target covered by 5 to 7 target lesion sub-units. Results: Good correlations were found between (1) the mean axial T2 lesion diameter intraoperatively and the mean 240 cumulative equivalent min at 43°C (240 CEM) thermal dose diameter (r = 0.52), (2) the mean axial T2 diameter 48 h post-treatment and the mean 18 CEM thermal dose diameter (r = 0.62), and (3) the mean axial T2 diameter intraoperatively and 48 h post-treatment (r = 0.62). Conclusion: Our current approach using a thermal dose steering for multiple target lesion sub-units could be reproduced in 31 interventions with a good lesion size predictability.
Collapse
Affiliation(s)
- Marc N Gallay
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| | - David Moser
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| | - Christian Federau
- ETH Zurich, Institute for Biomedical Engineering, University Zurich, Zurich, Switzerland.,Department of Radiology, University Hospital Basel, Basel, Switzerland
| | - Daniel Jeanmonod
- SoniModul, Center for Ultrasound Functional Neurosurgery, Solothurn, Switzerland
| |
Collapse
|
14
|
Dallapiazza RF, Lee DJ, De Vloo P, Fomenko A, Hamani C, Hodaie M, Kalia SK, Fasano A, Lozano AM. Outcomes from stereotactic surgery for essential tremor. J Neurol Neurosurg Psychiatry 2019; 90:474-482. [PMID: 30337440 PMCID: PMC6581115 DOI: 10.1136/jnnp-2018-318240] [Citation(s) in RCA: 125] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 07/17/2018] [Accepted: 09/25/2018] [Indexed: 11/03/2022]
Abstract
There are several different surgical procedures that are used to treat essential tremor (ET), including deep brain stimulation (DBS) and thalamotomy procedures with radiofrequency (RF), radiosurgery (RS) and most recently, focused ultrasound (FUS). Choosing a surgical treatment requires a careful presentation and discussion of the benefits and drawbacks of each. We conducted a literature review to compare the attributes and make an appraisal of these various procedures. DBS was the most commonly reported treatment for ET. One-year tremor reductions ranged from 53% to 63% with unilateral Vim DBS. Similar improvements were demonstrated with RF (range, 74%-90%), RS (range, 48%-63%) and FUS thalamotomy (range, 35%-75%). Overall, bilateral Vim DBS demonstrated more improvement in tremor reduction since both upper extremities were treated (range, 66%-78%). Several studies show continued beneficial effects from DBS up to five years. Long-term follow-up data also support RF and gamma knife radiosurgical thalamotomy treatments. Quality of life measures were similarly improved among patients who received all treatments. Paraesthesias, dysarthria and ataxia were commonly reported adverse effects in all treatment modalities and were more common with bilateral DBS surgery. Many of the neurological complications were transient and resolved after surgery. DBS surgery had the added benefit of programming adjustments to minimise stimulation-related complications. Permanent neurological complications were most commonly reported for RF thalamotomy. Thalamic DBS is an effective, safe treatment with a long history. For patients who are medically unfit or reluctant to undergo DBS, several thalamic lesioning methods have parallel benefits to unilateral DBS surgery. Each of these surgical modalities has its own nuance for treatment and patient selection. These factors should be carefully considered by both neurosurgeons and patients when selecting an appropriate treatment for ET.
Collapse
Affiliation(s)
| | - Darrin J Lee
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Philippe De Vloo
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Anton Fomenko
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Clement Hamani
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Mojgan Hodaie
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Suneil K Kalia
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| | - Alfonso Fasano
- Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.,Division of Neurology, University of Toronto, Toronto, Ontario, Canada.,Krembil Research Institute, Toronto, Ontario, Canada
| | - Andres M Lozano
- Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
15
|
Lee EJ, Fomenko A, Lozano AM. Magnetic Resonance-Guided Focused Ultrasound : Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening. J Korean Neurosurg Soc 2018; 62:10-26. [PMID: 30630292 PMCID: PMC6328789 DOI: 10.3340/jkns.2018.0180] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 11/13/2018] [Indexed: 02/06/2023] Open
Abstract
Magnetic resonance-guided focused ultrasound (MRgFUS) is an emerging new technology with considerable potential to treat various neurological diseases. With refinement of ultrasound transducer technology and integration with magnetic resonance imaging guidance, transcranial sonication of precise cerebral targets has become a therapeutic option. Intensity is a key determinant of ultrasound effects. High-intensity focused ultrasound can produce targeted lesions via thermal ablation of tissue. MRgFUS-mediated stereotactic ablation is non-invasive, incision-free, and confers immediate therapeutic effects. Since the US Food and Drug Administration approval of MRgFUS in 2016 for unilateral thalamotomy in medication-refractory essential tremor, studies on novel indications such as Parkinson's disease, psychiatric disease, and brain tumors are underway. MRgFUS is also used in the context of blood-brain barrier (BBB) opening at low intensities, in combination with intravenously-administered microbubbles. Preclinical studies show that MRgFUS-mediated BBB opening safely enhances the delivery of targeted chemotherapeutic agents to the brain and improves tumor control as well as survival. In addition, BBB opening has been shown to activate the innate immune system in animal models of Alzheimer's disease. Amyloid plaque clearance and promotion of neurogenesis in these studies suggest that MRgFUS-mediated BBB opening may be a new paradigm for neurodegenerative disease treatment in the future. Here, we review the current status of preclinical and clinical trials of MRgFUS-mediated thermal ablation and BBB opening, described their mechanisms of action, and discuss future prospects.
Collapse
Affiliation(s)
- Eun Jung Lee
- Toronto Western Research Institute, University Health Network, Toronto, Canada
| | - Anton Fomenko
- Toronto Western Research Institute, University Health Network, Toronto, Canada
| | - Andres M Lozano
- Toronto Western Research Institute, University Health Network, Toronto, Canada.,Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, University of Toronto, Toronto, Canada
| |
Collapse
|
16
|
Zafar A, Quadri SA, Farooqui M, Ortega-Gutiérrez S, Hariri OR, Zulfiqar M, Ikram A, Khan MA, Suriya SS, Nunez-Gonzalez JR, Posse S, Mortazavi MM, Yonas H. MRI-Guided High-Intensity Focused Ultrasound as an Emerging Therapy for Stroke: A Review. J Neuroimaging 2018; 29:5-13. [PMID: 30295987 DOI: 10.1111/jon.12568] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 09/21/2018] [Indexed: 01/23/2023] Open
Abstract
Stroke, either ischemic or hemorrhagic, accounts for significantly high morbidity and mortality rates around the globe effecting millions of lives annually. For the past few decades, ultrasound has been extensively investigated to promote clot lysis for the treatment of stroke, myocardial infarction, and acute peripheral arterial occlusions, with or without the use of tPA or contrast agents. In the age of modern minimal invasive techniques, magnetic resonance imaging-guided high-intensity focused ultrasound is a new emerging modality that seems to promise therapeutic utilities for both ischemic and hemorrhagic stroke. High-intensity focused ultrasound causes thermal heating as the tissue absorbs the mechanical energy transmitted by the ultrasonic waves leading to tissue denaturation and coagulation. Several in-vitro and in-vivo studies have demonstrated the viability of this technology for sonothrombolysis in both types of stroke and have warranted clinical trials. Apart from safety and efficacy, initiation of trials would further enable answers regarding its practical application in a clinical setup. Though this technology has been under study for treatment of various brain diseases for some decades now, relatively very few neurologists and even neurosurgeons seem to be acquainted with it. The aim of this review is to provide basic understanding of this powerful technology and discuss its clinical application and potential role as an emerging viable therapeutic option for the future management of stroke.
Collapse
Affiliation(s)
- Atif Zafar
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM
| | - Syed A Quadri
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM.,California Institute of Neuroscience, Thousand Oaks, CA.,National Skull Base Center, Thousand Oaks, CA
| | - Mudassir Farooqui
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM
| | | | - Omid R Hariri
- Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA
| | - Maryam Zulfiqar
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Asad Ikram
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM
| | - Muhammad Adnan Khan
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM.,California Institute of Neuroscience, Thousand Oaks, CA.,National Skull Base Center, Thousand Oaks, CA
| | - Sajid S Suriya
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM.,California Institute of Neuroscience, Thousand Oaks, CA.,National Skull Base Center, Thousand Oaks, CA
| | | | - Stefan Posse
- Department of Neurology, University of New Mexico Hospitals, Albuquerque, NM
| | - Martin M Mortazavi
- California Institute of Neuroscience, Thousand Oaks, CA.,National Skull Base Center, Thousand Oaks, CA
| | - Howard Yonas
- Department of Neurosurgery, University of New Mexico, Albuquerque, NM
| |
Collapse
|
17
|
Bretsztajn L, Gedroyc W. Brain-focussed ultrasound: what's the "FUS" all about? A review of current and emerging neurological applications. Br J Radiol 2018; 91:20170481. [PMID: 29419328 PMCID: PMC6221771 DOI: 10.1259/bjr.20170481] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Revised: 01/12/2018] [Accepted: 02/01/2018] [Indexed: 11/05/2022] Open
Abstract
MR-guided focussed ultrasound surgery (MRgFUS) allows for precise non-invasive thermal ablation of target tissues for a wide range of clinical applications. It is an innovative and rapidly expanding technology, which has already established itself as an effective and safe incisionless alternative in the treatment of various soft tissue tumours, with many more research studies underway to extend its therapeutic envelope. The non-invasiveness of the procedure makes FUS particularly attractive in functional neurosurgery, where existing treatment options are not suitable for all patients. Several clinical trials have demonstrated the feasibility and favourable safety profile of MR-guided focused ultrasound surgery in essential tremor, Parkinson's disease and other neurological conditions. This article reviews the existing evidence base for the neurological applications of FUS and the evidence for its emerging roles in the treatment of a range of brain disorders.
Collapse
Affiliation(s)
- Laure Bretsztajn
- Radiology Department, Imperial College Healthcare NHS Trust, London, United Kingdom
| | - Wladyslaw Gedroyc
- Radiology Department, Imperial College Healthcare NHS Trust, London, United Kingdom
| |
Collapse
|
18
|
Ito H, Fukutake S, Yamamoto K, Yamaguchi T, Taira T, Kamei T. Magnetic Resonance Imaging-guided Focused Ultrasound Thalamotomy for Parkinson's Disease. Intern Med 2018; 57:1027-1031. [PMID: 29269662 PMCID: PMC5919866 DOI: 10.2169/internalmedicine.9586-17] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Thalamotomy is effective in treating refractory tremor in Parkinson's disease (PD). We herein report a PD patient who underwent left ventral intermediate nucleus and ventro oralis posterior nucleus thalamotomy using magnetic resonance imaging-guided focused ultrasound (MRgFUS). Right-side resting tremor and rigidity were abolished immediately following the ultrasound energy delivery. In addition, left-side resting tremor and rigidity also improved. No adverse events occurred during the procedure. We observed the exacerbation of bradykinesia, which might have been caused by edema around the target. This is the first report of thalamotomy using MRgFUS for PD patient from Japan. Further investigations concerning the efficacy and safety of this procedure are necessary.
Collapse
Affiliation(s)
- Hisashi Ito
- Department of Neurology, Shonan Fujisawa Tokushukai Hospital, Japan
| | - Shigeru Fukutake
- Department of Neurology, Shonan Fujisawa Tokushukai Hospital, Japan
| | - Kazuaki Yamamoto
- Department of Neurosurgery, Shonan Kamakura General Hospital, Japan
| | - Toshio Yamaguchi
- Research Institute of Diagnostic Imaging, Shin-Yurigaoka General Hospital, Japan
| | - Takaomi Taira
- Department of Neurosurgery, Tokyo Women's Medical University, Japan
| | - Tetsumasa Kamei
- Department of Neurology, Shonan Fujisawa Tokushukai Hospital, Japan
| |
Collapse
|
19
|
Ultrasound Elicits Behavioral Responses through Mechanical Effects on Neurons and Ion Channels in a Simple Nervous System. J Neurosci 2018; 38:3081-3091. [PMID: 29463641 DOI: 10.1523/jneurosci.1458-17.2018] [Citation(s) in RCA: 155] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 01/11/2018] [Accepted: 01/27/2018] [Indexed: 01/07/2023] Open
Abstract
Focused ultrasound has been shown to stimulate excitable cells, but the biophysical mechanisms behind this phenomenon remain poorly understood. To provide additional insight, we devised a behavioral-genetic assay applied to the well-characterized nervous system of Caenorhabditis elegans nematodes. We found that pulsed ultrasound elicits robust reversal behavior in wild-type animals in a pressure-, duration-, and pulse protocol-dependent manner. Responses were preserved in mutants unable to sense thermal fluctuations and absent in mutants lacking neurons required for mechanosensation. Additionally, we found that the worm's response to ultrasound pulses rests on the expression of MEC-4, a DEG/ENaC/ASIC ion channel required for touch sensation. Consistent with prior studies of MEC-4-dependent currents in vivo, the worm's response was optimal for pulses repeated 300-1000 times per second. Based on these findings, we conclude that mechanical, rather than thermal, stimulation accounts for behavioral responses. Further, we propose that acoustic radiation force governs the response to ultrasound in a manner that depends on the touch receptor neurons and MEC-4-dependent ion channels. Our findings illuminate a complete pathway of ultrasound action, from the forces generated by propagating ultrasound to an activation of a specific ion channel. The findings further highlight the importance of optimizing ultrasound pulsing protocols when stimulating neurons via ion channels with mechanosensitive properties.SIGNIFICANCE STATEMENT How ultrasound influences neurons and other excitable cells has remained a mystery for decades. Although it is widely understood that ultrasound can heat tissues and induce mechanical strain, whether or not neuronal activation depends on heat, mechanical force, or both physical factors is not known. We harnessed Caenorhabditis elegans nematodes and their extraordinary sensitivity to thermal and mechanical stimuli to address this question. Whereas thermosensory mutants respond to ultrasound similar to wild-type animals, mechanosensory mutants were insensitive to ultrasound stimulation. Additionally, stimulus parameters that accentuate mechanical effects were more effective than those producing more heat. These findings highlight a mechanical nature of the effect of ultrasound on neurons and suggest specific ways to optimize stimulation protocols in specific tissues.
Collapse
|
20
|
Quadri SA, Waqas M, Khan I, Khan MA, Suriya SS, Farooqui M, Fiani B. High-intensity focused ultrasound: past, present, and future in neurosurgery. Neurosurg Focus 2018; 44:E16. [DOI: 10.3171/2017.11.focus17610] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Since Lynn and colleagues first described the use of focused ultrasound (FUS) waves for intracranial ablation in 1942, many strides have been made toward the treatment of several brain pathologies using this novel technology. In the modern era of minimal invasiveness, high-intensity focused ultrasound (HIFU) promises therapeutic utility for multiple neurosurgical applications, including treatment of tumors, stroke, epilepsy, and functional disorders. Although the use of HIFU as a potential therapeutic modality in the brain has been under study for several decades, relatively few neuroscientists, neurologists, or even neurosurgeons are familiar with it. In this extensive review, the authors intend to shed light on the current use of HIFU in different neurosurgical avenues and its mechanism of action, as well as provide an update on the outcome of various trials and advances expected from various preclinical studies in the near future. Although the initial technical challenges have been overcome and the technology has been improved, only very few clinical trials have thus far been carried out. The number of clinical trials related to neurological disorders is expected to increase in the coming years, as this novel therapeutic device appears to have a substantial expansive potential. There is great opportunity to expand the use of HIFU across various medical and surgical disciplines for the treatment of different pathologies. As this technology gains recognition, it will open the door for further research opportunities and innovation.
Collapse
Affiliation(s)
- Syed A. Quadri
- 1California Institute of Neuroscience, Thousand Oaks, California
| | - Muhammad Waqas
- 1California Institute of Neuroscience, Thousand Oaks, California
- 2Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan
| | - Inamullah Khan
- 2Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan
| | | | - Sajid S. Suriya
- 1California Institute of Neuroscience, Thousand Oaks, California
| | - Mudassir Farooqui
- 3University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; and
| | - Brian Fiani
- 4Department of Neurosurgery, Institute of Clinical Orthopedic and Neurosciences, Desert Regional Medical Center, Palm Springs, California
| |
Collapse
|
21
|
Kim YG, Chang JW. High-Intensity Focused Ultrasound Surgery for the Treatment of Obsessive–Compulsive Disorder. Neuromodulation 2018. [DOI: 10.1016/b978-0-12-805353-9.00086-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
|
23
|
Obeso J, Stamelou M, Goetz C, Poewe W, Lang A, Weintraub D, Burn D, Halliday G, Bezard E, Przedborski S, Lehericy S, Brooks D, Rothwell J, Hallett M, DeLong M, Marras C, Tanner C, Ross G, Langston J, Klein C, Bonifati V, Jankovic J, Lozano A, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma R, Berg D, Marek K, Standaert D, Surmeier D, Olanow C, Kordower J, Calabresi P, Schapira A, Stoessl A. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord 2017; 32:1264-1310. [PMID: 28887905 PMCID: PMC5685546 DOI: 10.1002/mds.27115] [Citation(s) in RCA: 481] [Impact Index Per Article: 68.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 06/27/2017] [Indexed: 12/12/2022] Open
Abstract
This article reviews and summarizes 200 years of Parkinson's disease. It comprises a relevant history of Dr. James Parkinson's himself and what he described accurately and what he missed from today's perspective. Parkinson's disease today is understood as a multietiological condition with uncertain etiopathogenesis. Many advances have occurred regarding pathophysiology and symptomatic treatments, but critically important issues are still pending resolution. Among the latter, the need to modify disease progression is undoubtedly a priority. In sum, this multiple-author article, prepared to commemorate the bicentenary of the shaking palsy, provides a historical state-of-the-art account of what has been achieved, the current situation, and how to progress toward resolving Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- J.A. Obeso
- HM CINAC, Hospital Universitario HM Puerta del Sur, Mostoles, Madrid, Spain
- Universidad CEU San Pablo, Madrid, Spain
- CIBERNED, Madrid, Spain
| | - M. Stamelou
- Department of Neurology, Philipps University, Marburg, Germany
- Parkinson’s Disease and Movement Disorders Department, HYGEIA Hospital and Attikon Hospital, University of Athens, Athens, Greece
| | - C.G. Goetz
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA
| | - W. Poewe
- Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
| | - A.E. Lang
- Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Canada
- Department of Medicine, University of Toronto, Toronto, Canada
| | - D. Weintraub
- Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Parkinson’s Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Corporal Michael J. Crescenz Veteran’s Affairs Medical Center, Philadelphia, Pennsylvania, USA
| | - D. Burn
- Medical Sciences, Newcastle University, Newcastle, UK
| | - G.M. Halliday
- Brain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia
- School of Medical Sciences, University of New South Wales and Neuroscience Research Australia, Sydney, Australia
| | - E. Bezard
- Université de Bordeaux, Institut des Maladies Neurodégénératives, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des Maladies Neurodégénératives, Bordeaux, France
- China Academy of Medical Sciences, Institute of Lab Animal Sciences, Beijing, China
| | - S. Przedborski
- Departments of Neurology, Pathology, and Cell Biology, the Center for Motor Neuron Biology and Disease, Columbia University, New York, New York, USA
- Columbia Translational Neuroscience Initiative, Columbia University, New York, New York, USA
| | - S. Lehericy
- Institut du Cerveau et de la Moelle épinière – ICM, Centre de NeuroImagerie de Recherche – CENIR, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France
- Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - D.J. Brooks
- Clinical Sciences Department, Newcastle University, Newcastle, UK
- Department of Nuclear Medicine, Aarhus University, Aarhus, Denmark
| | - J.C. Rothwell
- Human Neurophysiology, Sobell Department, UCL Institute of Neurology, London, UK
| | - M. Hallett
- Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | - M.R. DeLong
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - C. Marras
- Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson’s disease, Toronto Western Hospital, University of Toronto, Toronto, Canada
| | - C.M. Tanner
- Movement Disorders and Neuromodulation Center, Department of Neurology, University of California–San Francisco, San Francisco, California, USA
- Parkinson’s Disease Research, Education and Clinical Center, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
| | - G.W. Ross
- Veterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii, USA
| | | | - C. Klein
- Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
| | - V. Bonifati
- Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - J. Jankovic
- Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
| | - A.M. Lozano
- Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Canada
| | - G. Deuschl
- Department of Neurology, Universitätsklinikum Schleswig-Holstein, Christian Albrechts University Kiel, Kiel, Germany
| | - H. Bergman
- Department of Medical Neurobiology, Institute of Medical Research Israel-Canada, Jerusalem, Israel
- Edmond and Lily Safra Center for Brain Sciences, The Hebrew University, Jerusalem, Israel
- Department of Neurosurgery, Hadassah University Hospital, Jerusalem, Israel
| | - E. Tolosa
- Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain
- Department of Medicine, Universitat de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
| | - M. Rodriguez-Violante
- Movement Disorders Clinic, Clinical Neurodegenerative Research Unit, Mexico City, Mexico
- Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - S. Fahn
- Department of Neurology, Columbia University Medical Center, New York, New York, USA
| | - R.B. Postuma
- Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada
| | - D. Berg
- Klinikfür Neurologie, UKSH, Campus Kiel, Christian-Albrechts-Universität, Kiel, Germany
| | - K. Marek
- Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA
| | - D.G. Standaert
- Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - D.J. Surmeier
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - C.W. Olanow
- Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
| | - J.H. Kordower
- Research Center for Brain Repair, Rush University Medical Center, Chicago, Illinois, USA
- Neuroscience Graduate Program, Rush University Medical Center, Chicago, Illinois, USA
| | - P. Calabresi
- Neurological Clinic, Department of Medicine, Hospital Santa Maria della Misericordia, University of Perugia, Perugia, Italy
- Laboratory of Neurophysiology, Santa Lucia Foundation, IRCCS, Rome, Italy
| | - A.H.V. Schapira
- University Department of Clinical Neurosciences, UCL Institute of Neurology, University College London, London, UK
| | - A.J. Stoessl
- Pacific Parkinson’s Research Centre, Division of Neurology & Djavadf Mowafaghian Centre for Brain Health, University of British Columbia, British Columbia, Canada
- Vancouver Coastal Health, Vancouver, British Columbia, Canada
| |
Collapse
|
24
|
|
25
|
Cif L, Hariz M. Seventy Years with the Globus Pallidus: Pallidal Surgery for Movement Disorders Between 1947 and 2017. Mov Disord 2017; 32:972-982. [PMID: 28590521 DOI: 10.1002/mds.27054] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 04/20/2017] [Accepted: 04/23/2017] [Indexed: 12/25/2022] Open
Abstract
The year 2017 marks the 70th anniversary of the birth of human stereotactic neurosurgery. The first procedure was a pallidotomy for Huntington's disease. However, it was for Parkinson's disease that pallidotomy was soon adopted worldwide. Pallidotomy was abandoned in the late 1950s in favor of thalamotomy because of the latter's more striking effect on tremor. The advent of levodopa put a halt to all surgery for PD. In the mid-1980s, Laitinen reintroduced the posteroventral pallidotomy of Leksell, and this procedure spread worldwide thanks to its efficacy on most parkinsonian symptoms including levodopa-induced dyskinesias and thanks to basic scientific work confirming the role of the globus pallidus internus in the pathophysiology of PD. With the advent of deep brain stimulation of the subthalamic nucleus, pallidotomy was again abandoned, and even DBS of the GPi has been overshadowed by STN DBS. The GPi reemerged in the late 1990s as a major stereotactic target for DBS in dystonia and, recently, in Tourette syndrome. Lately, lesioning of the GPI is being proposed to treat refractory status dystonicus or to treat DBS withdrawal syndrome in PD patients. Hence, the pallidum as a stereotactic target for either lesioning or DBS has been the phoenix of functional stereotactic neurosurgery, constantly abandoned and then rising again from its ashes. This review is a tribute to the pallidum on its 70th anniversary as a surgical target for movement disorders, analyzing its ebbs and flows and highlighting its merits, its versatility, and its resilience. © 2017 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Laura Cif
- Unités des Pathologies Cérébrales Résistantes, Département de Neurochirurgie, Centre Hospitalier Universitaire, Montpellier, France.,Unité de Recherche sur les Comportements et Mouvements Anormaux (URCMA), Institut de Génomique Fonctionnelle, Université Montpellier, Montpellier, France
| | - Marwan Hariz
- Unit of Functional Neurosurgery, University College London-Institute of Neurology, Queen Square, London, UK.,Department of Clinical Neuroscience, Umeå University, Umeå, Sweden
| |
Collapse
|
26
|
Rohani M, Fasano A. Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. TREMOR AND OTHER HYPERKINETIC MOVEMENTS (NEW YORK, N.Y.) 2017; 7:462. [PMID: 28503363 PMCID: PMC5425801 DOI: 10.7916/d8z89jn1] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 04/17/2017] [Indexed: 01/09/2023]
Abstract
Background While there is no breakthrough progress in the medical treatment of essential tremor (ET), in the past decades several remarkable achievements happened in the surgical field, such as radiofrequency thalamotomy, thalamic deep brain stimulation, and gamma knife thalamotomy. The most recent advance in this area is magnetic resonance-guided focused ultrasound (MRgFUS). Methods The purpose of this review is to discuss the new developments and trials of MRgFUS in the treatment of ET and other tremor disorders. Results MRgFUS is an incisionless surgery performed without anesthesia and ionizing radiation (no risk of cumulative dose and delayed side effects). Studies have shown the safety and effectiveness of unilateral MRgFUS-thalamotomy in the treatment of ET. It has been successfully used in a few patients with Parkinson’s disease-related tremor, and in fewer patients with fragile X-associated tremor/ataxia syndrome. The safety and long-term effects of the procedure are still unclear, as temporary and permanent adverse events have been reported as well as recurrence of tremor. Discussion MRgFUS is a promising new surgical approach with a number of unknowns and unsolved issues. It represents a valuable option particularly for patients who refused or could not be candidates for other procedures, deep brain stimulation in particular.
Collapse
Affiliation(s)
- Mohammad Rohani
- Department of Neurology, Hazrat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran
| | - Alfonso Fasano
- Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital and Division of Neurology, University of Toronto, Toronto, Ontario, Canada.,Krembil Research Institute, Toronto, Ontario, Canada
| |
Collapse
|
27
|
Dallapiazza RF, Timbie KF, Holmberg S, Gatesman J, Lopes MB, Price RJ, Miller GW, Elias WJ. Noninvasive neuromodulation and thalamic mapping with low-intensity focused ultrasound. J Neurosurg 2017; 128:875-884. [PMID: 28430035 DOI: 10.3171/2016.11.jns16976] [Citation(s) in RCA: 133] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Ultrasound can be precisely focused through the intact human skull to target deep regions of the brain for stereotactic ablations. Acoustic energy at much lower intensities is capable of both exciting and inhibiting neural tissues without causing tissue heating or damage. The objective of this study was to demonstrate the effects of low-intensity focused ultrasound (LIFU) for neuromodulation and selective mapping in the thalamus of a large-brain animal. METHODS Ten Yorkshire swine ( Sus scrofa domesticus) were used in this study. In the first neuromodulation experiment, the lemniscal sensory thalamus was stereotactically targeted with LIFU, and somatosensory evoked potentials (SSEPs) were monitored. In a second mapping experiment, the ventromedial and ventroposterolateral sensory thalamic nuclei were alternately targeted with LIFU, while both trigeminal and tibial evoked SSEPs were recorded. Temperature at the acoustic focus was assessed using MR thermography. At the end of the experiments, all tissues were assessed histologically for damage. RESULTS LIFU targeted to the ventroposterolateral thalamic nucleus suppressed SSEP amplitude to 71.6% ± 11.4% (mean ± SD) compared with baseline recordings. Second, we found a similar degree of inhibition with a high spatial resolution (∼ 2 mm) since adjacent thalamic nuclei could be selectively inhibited. The ventromedial thalamic nucleus could be inhibited without affecting the ventrolateral nucleus. During MR thermography imaging, there was no observed tissue heating during LIFU sonications and no histological evidence of tissue damage. CONCLUSIONS These results suggest that LIFU can be safely used to modulate neuronal circuits in the central nervous system and that noninvasive brain mapping with focused ultrasound may be feasible in humans.
Collapse
Affiliation(s)
| | | | - Stephen Holmberg
- 6Impulse Monitoring, University of Virginia, Charlottesville, Virginia
| | | | | | | | | | | |
Collapse
|
28
|
MRI-Guided Focused Ultrasound in Parkinson's Disease: A Review. PARKINSONS DISEASE 2017; 2017:8124624. [PMID: 28465861 PMCID: PMC5390565 DOI: 10.1155/2017/8124624] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 03/01/2017] [Accepted: 03/15/2017] [Indexed: 11/17/2022]
Abstract
MRI-guided focused ultrasound is a new technology that enables intracranial ablation. Since lesioning ameliorates some of the symptoms of PD, this technology is being explored as a possible treatment for medication resistant symptoms in PD patients. The purpose of this paper is to review the clinical use and treatment outcomes of PD patients treated to date with this technology.
Collapse
|
29
|
Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah BB, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierney TS, Hayes MT, Cosgrove GR, Yamaguchi T, Abe K, Taira T, Chang JW. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N Engl J Med 2016; 375:730-9. [PMID: 27557301 DOI: 10.1056/nejmoa1600159] [Citation(s) in RCA: 649] [Impact Index Per Article: 81.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Uncontrolled pilot studies have suggested the efficacy of focused ultrasound thalamotomy with magnetic resonance imaging (MRI) guidance for the treatment of essential tremor. METHODS We enrolled patients with moderate-to-severe essential tremor that had not responded to at least two trials of medical therapy and randomly assigned them in a 3:1 ratio to undergo unilateral focused ultrasound thalamotomy or a sham procedure. The Clinical Rating Scale for Tremor and the Quality of Life in Essential Tremor Questionnaire were administered at baseline and at 1, 3, 6, and 12 months. Tremor assessments were videotaped and rated by an independent group of neurologists who were unaware of the treatment assignments. The primary outcome was the between-group difference in the change from baseline to 3 months in hand tremor, rated on a 32-point scale (with higher scores indicating more severe tremor). After 3 months, patients in the sham-procedure group could cross over to active treatment (the open-label extension cohort). RESULTS Seventy-six patients were included in the analysis. Hand-tremor scores improved more after focused ultrasound thalamotomy (from 18.1 points at baseline to 9.6 at 3 months) than after the sham procedure (from 16.0 to 15.8 points); the between-group difference in the mean change was 8.3 points (95% confidence interval [CI], 5.9 to 10.7; P<0.001). The improvement in the thalamotomy group was maintained at 12 months (change from baseline, 7.2 points; 95% CI, 6.1 to 8.3). Secondary outcome measures assessing disability and quality of life also improved with active treatment (the blinded thalamotomy cohort)as compared with the sham procedure (P<0.001 for both comparisons). Adverse events in the thalamotomy group included gait disturbance in 36% of patients and paresthesias or numbness in 38%; these adverse events persisted at 12 months in 9% and 14% of patients, respectively. CONCLUSIONS MRI-guided focused ultrasound thalamotomy reduced hand tremor in patients with essential tremor. Side effects included sensory and gait disturbances. (Funded by InSightec and others; ClinicalTrials.gov number, NCT01827904.).
Collapse
Affiliation(s)
- W Jeffrey Elias
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Nir Lipsman
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - William G Ondo
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Pejman Ghanouni
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Young G Kim
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Wonhee Lee
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Michael Schwartz
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Kullervo Hynynen
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Andres M Lozano
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Binit B Shah
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Diane Huss
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Robert F Dallapiazza
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Ryder Gwinn
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Jennifer Witt
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Susie Ro
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Howard M Eisenberg
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Paul S Fishman
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Dheeraj Gandhi
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Casey H Halpern
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Rosalind Chuang
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Kim Butts Pauly
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Travis S Tierney
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Michael T Hayes
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - G Rees Cosgrove
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Toshio Yamaguchi
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Keiichi Abe
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Takaomi Taira
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| | - Jin W Chang
- From the University of Virginia Health Sciences Center, Charlottesville (W.J.E., B.B.S., D.H., R.F.D.); Toronto Western Hospital (N.L., A.M.L.) and Sunnybrook Health Sciences Centre (M.S., K.H.), Toronto; Methodist Neurological Institute, Houston (W.G.O.); Stanford University School of Medicine, Stanford, CA (P.G., C.H.H., K.B.P.); Yonsei University College of Medicine, Seoul, South Korea (Y.G.K., W.L., J.W.C.); Swedish Neuroscience Institute, Seattle (R.G., J.W., S.R., R.C.); University of Maryland School of Medicine, Baltimore (H.M.E., P.S.F., D.G.); University of Miami School of Medicine, Nicklaus Children's Hospital, Miami (T.S.T.); Brigham and Women's Hospital, Boston (M.T.H., G.R.C.); and Shin-yurigaoka General Hospital, Kawasaki (T.Y.), and Tokyo Women's Medical University, Tokyo (K.A., T.T.) - both in Japan
| |
Collapse
|
30
|
Galkin MV. [The use of transcranial focused ultrasound in CNS diseases]. ZHURNAL VOPROSY NEĬROKHIRURGII IMENI N. N. BURDENKO 2016; 80:108-118. [PMID: 27331236 DOI: 10.17116/neiro2016802108-118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Transcranial focused ultrasound is a modern medical technique, which provides non-invasive impact on the brain. Current development stage of this technique is no longer than 20 years and many possible applications of this technique are still at pre-clinical stage. The greatest progress has been made in the field of functional neurosurgery. Focused ultrasound enables non-invasive MRI-guided formation of small destruction foci in the relevant targets, providing therapeutic neuromodulating effects in patients with Parkinson's disease, essential tremor, pain syndromes, obsessive-compulsive disorders, and other diseases. So far, this treatment was carried out in more than 300 patients. Several cases of ultrasound thermal destruction of intracranial neoplasms were published. There are attempts to perform third ventriculostomy using ultrasound in animals. A separate area focuses on the enhancement of the permeability of the blood-brain barrier to various substances driven by focused ultrasound. The possibilities of enhancing the permeability to chemotherapeutic agents, immune drugs, and other substances are being investigated in laboratories. A large number of studies focus on treatment of Alzheimer's disease. clinical trials aimed at enhancing the permeability of the blood-brain barrier to chemotherapeutic agents have been initiated. Reversible neuromodulating, stimulating, and inhibiting effect of focused ultrasound on the nervous system structures is another non-destructive effect, which is currently being actively investigated in animals. Furthermore, laboratory studies demonstrated the ability of focused ultrasound to destroy blood clots and thrombi. Transcranial focused ultrasound provides numerous unique possibilities for scientific and practical medicine. Large-scale research is required prior to the widespread clinical implementation. Nevertheless, we can already state that implementation of this technique will significantly enhance diagnostic and therapeutic potential of neurosurgery and neurology.
Collapse
Affiliation(s)
- M V Galkin
- Burdenko Neurosurgical Institute, Moscow, Russia
| |
Collapse
|
31
|
Weintraub D, Elias WJ. The emerging role of transcranial magnetic resonance imaging-guided focused ultrasound in functional neurosurgery. Mov Disord 2016; 32:20-27. [DOI: 10.1002/mds.26599] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 02/04/2016] [Indexed: 01/21/2023] Open
Affiliation(s)
- David Weintraub
- Department of Neurosurgery; University of Virginia; Charlottesville Virginia USA
| | - W. Jeffrey Elias
- Department of Neurosurgery; University of Virginia; Charlottesville Virginia USA
| |
Collapse
|
32
|
Focused ultrasound to transiently disrupt the blood brain barrier. J Clin Neurosci 2016; 28:187-9. [PMID: 26883350 DOI: 10.1016/j.jocn.2015.12.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Accepted: 12/17/2015] [Indexed: 10/22/2022]
|
33
|
Abel TJ, Walch T, Howard MA. Russell Meyers (1905-1999): pioneer of functional and ultrasonic neurosurgery. J Neurosurg 2016; 125:1589-1595. [PMID: 26871378 DOI: 10.3171/2015.9.jns142811] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Advances in functional neurosurgery, including neuromodulation and more recently ultrasonic ablation of basal ganglia structures, have improved the quality of life for patients with debilitating movement disorders. What is little known, however, is that both of these neurosurgical advances, which remain on the cutting edge, have their origin in the pioneering work of Russell Meyers, whose contributions are documented in this paper. Meyers' published work and professional correspondence are reviewed, in addition to documents held by the Department of Neurosurgery at the University of Iowa. Meyers was born in Brooklyn, New York, and received his neurosurgical training at hospitals in New York City under Jefferson Browder. In 1939, a chance encounter with a young woman with damaged bilateral ventral striata convinced Meyers that the caudate could be resected to treat Parkinsonism without disrupting consciousness. Shortly thereafter, he performed the first caudate resection for postencephalitic Parkinsonism. In 1946, Meyers became the first chairman of neurosurgery at the State University of Iowa (now the University of Iowa), which led to the recruitment of 8 faculty members and the training of 18 residents during his tenure (1946-1963). Through collaboration with the Fry brothers at the University of Illinois, Meyers performed the first stereotactic ultrasonic ablations of deep brain structures to treat tremor, choreoathetosis, dystonia, intractable pain, and hypothalamic hamartoma. Meyers left academic neurosurgery in 1963 for reasons that are unclear, but he continued clinical neurosurgery work for several more years. Despite his early departure from academic medicine, Meyers' contributions to functional neurosurgery provided a lasting legacy that has improved the lives of many patients with movement disorders.
Collapse
Affiliation(s)
- Taylor J Abel
- Department of Neurosurgery, University of Iowa, Iowa City, Iowa
| | - Timothy Walch
- Department of Neurosurgery, University of Iowa, Iowa City, Iowa
| | | |
Collapse
|
34
|
McDannold N, Zhang Y, Vykhodtseva N. Nonthermal ablation in the rat brain using focused ultrasound and an ultrasound contrast agent: long-term effects. J Neurosurg 2016; 125:1539-1548. [PMID: 26848919 DOI: 10.3171/2015.10.jns151525] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Thermal ablation with transcranial MRI-guided focused ultrasound (FUS) is currently under investigation as a less invasive alternative to radiosurgery and resection. A major limitation of the method is that its use is currently restricted to centrally located brain targets. The combination of FUS and a microbubble-based ultrasound contrast agent greatly reduces the ultrasound exposure level needed to ablate brain tissue and could be an effective means to increase the "treatment envelope" for FUS in the brain. This method, however, ablates tissue through a different mechanism: destruction of the microvasculature. It is not known whether nonthermal FUS ablation in substantial volumes of tissue can safely be performed without unexpected effects. The authors investigated this question by ablating volumes in the brains of normal rats. METHODS Overlapping sonications were performed in rats (n = 15) to ablate a volume in 1 hemisphere per animal. The sonications (10-msec bursts at 1 Hz for 60 seconds; peak negative pressure 0.8 MPa) were combined with the ultrasound contrast agent Optison (100 µl/kg). The rats were followed with MRI for 4-9 weeks after FUS, and the brains were examined with histological methods. RESULTS Two weeks after sonication and later, the lesions appeared as cyst-like areas in T2-weighted MR images that were stable over time. Histological examination demonstrated well-defined lesions consisting of a cyst-like cavity that remained lined by astrocytic tissue. Some white matter structures within the sonicated area were partially intact. CONCLUSIONS The results of this study indicate that nonthermal FUS ablation can be used to safely ablate tissue volumes in the brain without unexpected delayed effects. The findings are encouraging for the use of this ablation method in the brain.
Collapse
Affiliation(s)
- Nathan McDannold
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Yongzhi Zhang
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Natalia Vykhodtseva
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
35
|
Haritonova A, Liu D, Ebbini ES. In Vivo application and localization of transcranial focused ultrasound using dual-mode ultrasound arrays. IEEE TRANSACTIONS ON ULTRASONICS, FERROELECTRICS, AND FREQUENCY CONTROL 2015; 62:2031-42. [PMID: 26670845 PMCID: PMC4683405 DOI: 10.1109/tuffc.2014.006882] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Focused ultrasound (FUS) has been proposed for a variety of transcranial applications, including neuromodulation, tumor ablation, and blood-brain barrier opening. A flurry of activity in recent years has generated encouraging results demonstrating its feasibility in these and other applications. To date, monitoring of FUS beams has been primarily accomplished using MR guidance, where both MR thermography and elastography have been used. The recent introduction of real-time dual-mode ultrasound array (DMUA) systems offers a new paradigm in transcranial focusing. In this paper, we present first experimental results of ultrasound-guided transcranial FUS (tFUS) application in a rodent brain, both ex vivo and in vivo. DMUA imaging is used for visualization of the treatment region for placement of the focal spot within the brain. This includes the detection and localization of pulsating blood vessels at or near the target point(s). In addition, DMUA imaging is used to monitor and localize the FUS-tissue interactions in real time. In particular, a concave (40 mm radius of curvature), 32-element, 3.5-MHz DMUA prototype was used for imaging and tFUS application in ex vivo and in vivo rat models. The ex vivo experiments were used to evaluate the point spread function of the transcranial DMUA imaging at various points within the brain. In addition, DMUA-based transcranial ultrasound thermography measurements were compared with thermocouple measurements of subtherapeutic tFUS heating in rat brain ex vivo. The ex vivo setting was also used to demonstrate the capability of DMUA to produce localized thermal lesions. The in vivo experiments were designed to demonstrate the ability of the DMUA to apply, monitor, and localize subtherapeutic tFUS patterns that could be beneficial in transient blood-brain barrier opening. The results show that although the DMUA focus is degraded due to the propagation through the skull, it still produces localized heating effects within a sub-millimeter volume. In addition, DMUA transcranial echo data from brain tissue allow for reliable estimation of temperature change.
Collapse
Affiliation(s)
- Alyona Haritonova
- Department of Biomedical Engineering, University of Minnesota Twin Cities
| | - Dalong Liu
- Department of Electrical and Computer Engineering, University of Minnesota Twin Cities
| | - Emad S. Ebbini
- Department of Electrical and Computer Engineering, University of Minnesota Twin Cities
| |
Collapse
|
36
|
|
37
|
Sagias G, Yiallouras C, Ioannides K, Damianou C. An MRI-conditional motion phantom for the evaluation of high-intensity focused ultrasound protocols. Int J Med Robot 2015; 12:431-41. [PMID: 27593511 DOI: 10.1002/rcs.1709] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/27/2015] [Indexed: 11/11/2022]
Abstract
BACKGROUND The respiratory motion of abdominal organs is a serious obstacle in high-intensity focused ultrasound (HIFU) treatment with magnetic resonance imaging (MRI) guidance. In this study, a two-dimensional (2D) MRI-conditional motion phantom device was developed in order to evaluate HIFU protocols in synchronized and non-synchronized ablation of moving targets. MATERIALS AND METHODS The 2D phantom device simulates the respiratory motion of moving organs in both the left-right and craniocaudal directions. The device consists of MR-conditional materials which have been produced by a three-dimensional (3D) printer. RESULTS The MRI compatibility of the motion phantom was tested successfully in an MRI scanner. In vitro experiments were carried out to evaluate HIFU ablation protocols that are minimally affected by target motion. CONCLUSION It was shown that only in synchronized mode does HIFU produce thermal lesions, as tested on a gel phantom mimicking the moving target. The MRI-conditional phantom device was shown to be functional for its purpose and can be used as an evaluation tool for testing HIFU protocols for moving targets in an MRI environment. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
|
38
|
Wang TR, Dallapiazza R, Elias WJ. Neurological applications of transcranial high intensity focused ultrasound. Int J Hyperthermia 2015; 31:285-91. [PMID: 25703389 DOI: 10.3109/02656736.2015.1007398] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Advances in transcranial MRI-guided focused ultrasound have renewed interest in lesioning procedures in functional neurosurgery with a potential role in the treatment of neurological conditions such as chronic pain, brain tumours, movement disorders and psychiatric diseases. While the use of transcranial MRI-guided focused ultrasound represents a new innovation in neurosurgery, ultrasound has been used in neurosurgery for almost 60 years. This paper reviews the major historical milestones that have led to modern transcranial focused ultrasound and discusses current and evolving applications of ultrasound in the brain.
Collapse
Affiliation(s)
- Tony R Wang
- Department of Neurological Surgery, University of Virginia Health Sciences Center , Charlottesville, Virginia , USA
| | | | | |
Collapse
|
39
|
Dobrakowski PP, Machowska-Majchrzak AK, Labuz-Roszak B, Majchrzak KG, Kluczewska E, Pierzchała KB. MR-guided focused ultrasound: a new generation treatment of Parkinson's disease, essential tremor and neuropathic pain. Interv Neuroradiol 2014; 20:275-82. [PMID: 24976088 DOI: 10.15274/inr-2014-10033] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Accepted: 01/26/2014] [Indexed: 12/16/2022] Open
Abstract
The application of high intense focused ultrasound (HIFU) is currently the subject of many experimental and clinical trials. The combination of HIFU with MRI guidance known as MR-guided focused ultrasound (MRgFUS) appears to be particularly promising to ablate tissues located deep in the brain. The method can be the beginning of interventional neurology and an important alternative to neurosurgery. Studies conducted to date show the effectiveness of the method both in chronic diseases and in emergency cases. The safety and effectiveness of this method have been observed in parkinsonian and essential tremor as well as in neuropathic pain. The procedure does not require anaesthesia. Ionizing radiation is not used and there is no risk of cumulative dose. Such advantages may result in low complication rates and medical justification for further development of MRgFUS.
Collapse
Affiliation(s)
| | | | - Beata Labuz-Roszak
- Clinical Department of Neurology, Medical University of Silesia; Zabrze, Poland
| | | | - Ewa Kluczewska
- Clinical Department of Neurology, Medical University of Silesia; Zabrze, Poland
| | | |
Collapse
|
40
|
Wintermark M, Tustison NJ, Elias WJ, Patrie JT, Xin W, Demartini N, Eames M, Sumer S, Lau B, Cupino A, Snell J, Hananel A, Kassell N, Aubry JF. T1-weighted MRI as a substitute to CT for refocusing planning in MR-guided focused ultrasound. Phys Med Biol 2014; 59:3599-614. [DOI: 10.1088/0031-9155/59/13/3599] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
41
|
Aryal M, Arvanitis CD, Alexander PM, McDannold N. Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev 2014; 72:94-109. [PMID: 24462453 DOI: 10.1016/j.addr.2014.01.008] [Citation(s) in RCA: 263] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 12/30/2013] [Accepted: 01/14/2014] [Indexed: 12/24/2022]
Abstract
The physiology of the vasculature in the central nervous system (CNS), which includes the blood-brain barrier (BBB) and other factors, complicates the delivery of most drugs to the brain. Different methods have been used to bypass the BBB, but they have limitations such as being invasive, non-targeted or requiring the formulation of new drugs. Focused ultrasound (FUS), when combined with circulating microbubbles, is a noninvasive method to locally and transiently disrupt the BBB at discrete targets. This review provides insight on the current status of this unique drug delivery technique, experience in preclinical models, and potential for clinical translation. If translated to humans, this method would offer a flexible means to target therapeutics to desired points or volumes in the brain, and enable the whole arsenal of drugs in the CNS that are currently prevented by the BBB.
Collapse
Affiliation(s)
- Muna Aryal
- Department of Physics, Boston College, Chestnut Hill, USA; Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA
| | - Costas D Arvanitis
- Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA
| | - Phillip M Alexander
- Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA; Institute of Biomedical Engineering, Department of Engineering Science, and Brasenose College, University of Oxford, Oxford, UK
| | - Nathan McDannold
- Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA.
| |
Collapse
|
42
|
Tyshlek D, Aubry JF, ter Haar G, Hananel A, Foley J, Eames M, Kassell N, Simonin HH. Focused ultrasound development and clinical adoption: 2013 update on the growth of the field. J Ther Ultrasound 2014; 2:2. [PMID: 25512866 PMCID: PMC4265987 DOI: 10.1186/2050-5736-2-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Accepted: 01/24/2014] [Indexed: 12/12/2022] Open
Abstract
The field of therapeutic focused ultrasound, which first emerged in the 1940s, has seen significant growth, particularly over the past decade. The eventual widespread clinical adoption of this non-invasive therapeutic modality require continued progress, in a multitude of activities including technical, pre-clinical, and clinical research, regulatory approval and reimbursement, manufacturer growth, and other commercial and public sector investments into the field, all within a multi-stakeholder environment. We present here a snapshot of the field of focused ultrasound and describe how it has progressed over the past several decades. It is assessed using metrics which include quantity and breadth of academic work (presentations, publications), funding trends, manufacturer presence in the field, number of treated patients, number of indications reaching first-in-human status, and quantity and breadth of clinical indications.
Collapse
Affiliation(s)
- Dasha Tyshlek
- Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
| | - Jean-Francois Aubry
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22901, USA
- Institut Langevin, CNRS UMR 7587, ESPCI ParisTech, INSERM U979, Paris 75005, France
| | - Gail ter Haar
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
| | - Arik Hananel
- Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22901, USA
| | - Jessica Foley
- Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
| | - Matthew Eames
- Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
| | - Neal Kassell
- Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
- Department of Neurosurgery, University of Virginia, Charlottesville, VA 22901, USA
| | | |
Collapse
|
43
|
Nazer B, Gerstenfeld EP, Hata A, Crum LA, Matula TJ. Cardiovascular applications of therapeutic ultrasound. J Interv Card Electrophysiol 2013; 39:287-94. [PMID: 24297498 DOI: 10.1007/s10840-013-9845-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2013] [Accepted: 09/17/2013] [Indexed: 11/25/2022]
Abstract
Ultrasound (US) has gained widespread use in diagnostic cardiovascular applications. At amplitudes and frequencies typical of diagnostic use, its biomechanical effects on tissue are largely negligible. However, these parameters can be altered to harness US's thermal and non-thermal effects for therapeutic indications. High-intensity focused ultrasound (HIFU) and extracorporeal shock wave therapy (ECWT) are two therapeutic US modalities which have been investigated for treating cardiac arrhythmias and ischemic heart disease, respectively. Here, we review the biomechanical effects of HIFU and ECWT, their potential therapeutic mechanisms, and pre-clinical and clinical studies demonstrating their efficacy and safety limitations. Furthermore, we discuss other potential clinical applications of therapeutic US and areas in which future research is needed.
Collapse
Affiliation(s)
- Babak Nazer
- Division of Cardiology, University of California San Francisco, 505 Parnassus Avenue, Room M1184, San Francisco, CA, 94143-0124, USA,
| | | | | | | | | |
Collapse
|
44
|
Abstract
Transcranial MRI-guided focused ultrasound (TcMRgFUS) is an old idea but a new technology that may change the entire clinical field of the neurosciences. TcMRgFUS has no cumulative effect, and it is applicable for repeatable treatments, controlled by real-time dosimetry, and capable of immediate tissue destruction. Most importantly, it has extremely accurate targeting and constant monitoring. It is potentially more precise than proton beam therapy and definitely more cost effective. Neuro-oncology may be the most promising area of future TcMRgFUS applications.
Collapse
|
45
|
Elias WJ, Huss D, Voss T, Loomba J, Khaled M, Zadicario E, Frysinger RC, Sperling SA, Wylie S, Monteith SJ, Druzgal J, Shah BB, Harrison M, Wintermark M. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2013; 369:640-8. [PMID: 23944301 DOI: 10.1056/nejmoa1300962] [Citation(s) in RCA: 573] [Impact Index Per Article: 52.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Recent advances have enabled delivery of high-intensity focused ultrasound through the intact human cranium with magnetic resonance imaging (MRI) guidance. This preliminary study investigates the use of transcranial MRI-guided focused ultrasound thalamotomy for the treatment of essential tremor. METHODS From February 2011 through December 2011, in an open-label, uncontrolled study, we used transcranial MRI-guided focused ultrasound to target the unilateral ventral intermediate nucleus of the thalamus in 15 patients with severe, medication-refractory essential tremor. We recorded all safety data and measured the effectiveness of tremor suppression using the Clinical Rating Scale for Tremor to calculate the total score (ranging from 0 to 160), hand subscore (primary outcome, ranging from 0 to 32), and disability subscore (ranging from 0 to 32), with higher scores indicating worse tremor. We assessed the patients' perceptions of treatment efficacy with the Quality of Life in Essential Tremor Questionnaire (ranging from 0 to 100%, with higher scores indicating greater perceived disability). RESULTS Thermal ablation of the thalamic target occurred in all patients. Adverse effects of the procedure included transient sensory, cerebellar, motor, and speech abnormalities, with persistent paresthesias in four patients. Scores for hand tremor improved from 20.4 at baseline to 5.2 at 12 months (P=0.001). Total tremor scores improved from 54.9 to 24.3 (P=0.001). Disability scores improved from 18.2 to 2.8 (P=0.001). Quality-of-life scores improved from 37% to 11% (P=0.001). CONCLUSIONS In this pilot study, essential tremor improved in 15 patients treated with MRI-guided focused ultrasound thalamotomy. Large, randomized, controlled trials will be required to assess the procedure's efficacy and safety. (Funded by the Focused Ultrasound Surgery Foundation; ClinicalTrials.gov number, NCT01304758.).
Collapse
Affiliation(s)
- W Jeffrey Elias
- Department of Neurosurgery, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Foley JL, Eames M, Snell J, Hananel A, Kassell N, Aubry JF. Image-guided focused ultrasound: state of the technology and the challenges that lie ahead. ACTA ACUST UNITED AC 2013. [DOI: 10.2217/iim.13.38] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
47
|
Elias WJ, Khaled M, Hilliard JD, Aubry JF, Frysinger RC, Sheehan JP, Wintermark M, Lopes MB. A magnetic resonance imaging, histological, and dose modeling comparison of focused ultrasound, radiofrequency, and Gamma Knife radiosurgery lesions in swine thalamus. J Neurosurg 2013; 119:307-17. [DOI: 10.3171/2013.5.jns122327] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
The purpose of this study was to use MRI and histology to compare stereotactic lesioning modalities in a large brain model of thalamotomy.
Methods
A unilateral thalamotomy was performed in piglets utilizing one of 3 stereotactic lesioning modalities: focused ultrasound (FUS), radiofrequency, and radiosurgery. Standard clinical lesioning parameters were used for each treatment; and clinical, MRI, and histological assessments were made at early (< 72 hours), subacute (1 week), and later (1–3 months) time intervals.
Results
Histological and MRI assessment showed similar development for FUS and radiofrequency lesions. T2-weighted MRI revealed 3 concentric lesional zones at 48 hours with resolution of perilesional edema by 1 week. Acute ischemic infarction with macrophage infiltration was most prominent at 72 hours, with subsequent resolution of the inflammatory reaction and coalescence of the necrotic zone. There was no apparent difference in ischemic penumbra or “sharpness” between FUS or radiofrequency lesions. The radiosurgery lesions presented differently, with latent effects, less circumscribed lesions at 3 months, and apparent histological changes seen in white matter beyond the thalamic target. Additionally, thermal and radiation lesioning gradients were compared with modeling by dose to examine the theoretical penumbra.
Conclusions
In swine thalamus, FUS and radiosurgery lesions evolve similarly as determined by MRI, histological examination, and theoretical modeling. Radiosurgery produces lesions with more delayed effects and seemed to result in changes in the white matter beyond the thalamic target.
Collapse
|
48
|
|
49
|
Colen RR, Jolesz FA. MR-Guided Focused Ultrasound of the Brain. INTERVENTIONAL MAGNETIC RESONANCE IMAGING 2012. [DOI: 10.1007/174_2012_616] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
50
|
Tempany CMC, McDannold NJ, Hynynen K, Jolesz FA. Focused ultrasound surgery in oncology: overview and principles. Radiology 2011; 259:39-56. [PMID: 21436096 DOI: 10.1148/radiol.11100155] [Citation(s) in RCA: 161] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Focused ultrasound surgery (FUS) is a noninvasive image-guided therapy and an alternative to surgical interventions. It presents an opportunity to revolutionize cancer therapy and to affect or change drug delivery of therapeutic agents in new focally targeted ways. In this article the background, principles, technical devices, and clinical cancer applications of image-guided FUS are reviewed.
Collapse
Affiliation(s)
- Clare M C Tempany
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Room 050, L1, Boston, MA 02129, USA.
| | | | | | | |
Collapse
|